Stifel initiated coverage of Krystal Biotech with a Buy rating and $102 price target. The company brings a promising and exciting twist to the growing community of gene therapy companies, the analyst tells investors in a research note. Pioneering the use of engineered Herpes Simplex Virus, Krystal offers two important milestones that warrant optimism: topically-administered beremagene geperpavec that is near FDA decision with PDUFA on May 19 in dystrophic epidermolysis bullosa and the expansion opportunities including cystic fibrosis, the firm added.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRYS:
- Goldman Sachs Sees Over 60% Upside in These 3 Lesser-Known Stocks — Here’s Why They Could Jump
- Krystal Biotech appoints Catherine Mazzaco to boad of directors
- Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
- Krystal Biotech director Rossi sells 40,000 common shares
- Krystal Biotech upgraded to Buy from Neutral at Goldman Sachs
